ddhCTP

Overview

ddhCTP is an endogenously produced pyrimidine base analog with a K d of 17.0 nM for LLDH and an IC 50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.

Application

Products | Products > Disease Areas > Infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Endogenous Metabolite | Products > Signaling Pathways > Flavivirus | Products > Signaling Pathways > Lactate Dehydrogenase

Product Information

• Catalog No.: HY-128788
• CAS No.: 2279171-34-3
• Molecular Formula: C9H14N3O13P3
• Molecular Weight: 465.14
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source